Gerd Bader
- Oncology top 5%
- Molecular Biology top 5%
- Natural product bioactivities and synthesis 19
- Protein Degradation and Inhibitors 6
- Plant biochemistry and biosynthesis 5
- Protein Structure and Dynamics 3
- Cancer Research top 10%
- Drug Discovery top 10%
-
- Phytochemistry and Biological Activities 6
-
- Metabolism and Genetic Disorders 4
-
- Enzyme Structure and Function 4
-
- Toxin Mechanisms and Immunotoxins 3
- Co-authors
- Andreas ZoephelPilar Garin‐ChesaJens QuantUlrike Tontsch-GruntWolfgang J. RettigMartin KrššákFrank HilbergWolfgang Sommergruber
- Partner nations
- GermanyAustriaUnited States
In The Last Decade
Gerd Bader
51 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 841
- Pulmonary and Respiratory Medicine 967
- Molecular Biology 1.5k
- Cancer Research 181
- Drug Discovery 2
Countries citing papers authored by Gerd Bader
This map shows the geographic impact of Gerd Bader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerd Bader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerd Bader more than expected).
Fields of papers citing papers by Gerd Bader
This network shows the impact of papers produced by Gerd Bader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerd Bader. The network helps show where Gerd Bader may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gerd Bader, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2023 | 20 | |
| 4 | 2023 | 3 | |
| 5 | 2020 | 1 | |
| 6 | 2020 | 13 | |
| 7 | 2020 | 57 | |
| 8 | 2019 | 91 | |
| 9 | 2018 | 26 | |
| 10 | 2016 | 28 | |
| 11 | 2016 | 68 | |
| 12 | 2016 | 134 | |
| 13 | Antimicrobial studies of rhizome of Swertia petiolata | 2014 | 11 |
| 14 | Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blockerbreakdown → | 2012 | 684 |
| 15 | BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacybreakdown → | 2008 | 861 |
| 16 | 2004 | 11 | |
| 17 | 2003 | 60 | |
| 18 | European goldenrod as an anti-inflammatory drug: investigations into the cyto- and molecular pharmacology for a better understanding of the anti-inflammatory activity of preparations from Solidago virgaurea. | 2000 | 2 |
| 19 | 2000 | 88 | |
| 20 | 1992 | 12 |
About Gerd Bader
Gerd Bader is a scholar working on Molecular Biology, Clinical Biochemistry, Pharmacology, Complementary and alternative medicine and Biochemistry, having authored 54 papers that have together received 2.7k indexed citations. Recurring topics across this work include Natural product bioactivities and synthesis (19 papers), Phytochemistry and Biological Activities (6 papers), Protein Degradation and Inhibitors (6 papers), Plant biochemistry and biosynthesis (5 papers), Metabolism and Genetic Disorders (4 papers), Enzyme Structure and Function (4 papers), Toxin Mechanisms and Immunotoxins (3 papers) and Protein Structure and Dynamics (3 papers). The work is most often cited by research in Oncology (841 citations), Pulmonary and Respiratory Medicine (967 citations), Molecular Biology (1.5k citations), Cancer Research (181 citations) and Drug Discovery (2 citations). Gerd Bader has collaborated with scholars based in Germany, Austria and United States. Frequent co-authors include Andreas Zoephel, Pilar Garin‐Chesa, Jens Quant, Ulrike Tontsch-Grunt, Wolfgang J. Rettig, Martin Krššák, Frank Hilberg, Wolfgang Sommergruber, Armin Heckel and Gerald J. Roth. Their work appears in journals such as Planta Medica, Cancer Research, Journal of Molecular Biology, Nature Communications and ChemMedChem.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.